Johnson & Johnson: Colitis trials

The registry lists 21 Colitis studies with Johnson & Johnson as lead sponsor. 1 are open to participants now and 9 have results posted.

Phase 1 2Phase 2 4Phase 3 11Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi ArabiaRecruitingNCT07541261
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT02407236Phase 3Results posted
• A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.CompletedNCT01863771Phase 3Results posted
• A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)CompletedNCT01804166Phase 4Results posted
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)CompletedNCT01369355Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)CompletedNCT01369342Phase 3Results posted
• An Efficacy and Safety Study of Golimumab in Participants With Ulcerative ColitisTerminatedNCT00488774Phase 2/3Results posted
• An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT00488631Phase 3Results posted
• An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT00487539Phase 2/3Results posted
• A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative ColitisCompletedNCT00336492Phase 3Results posted
• A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical PracticeCompletedNCT04963725
• A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative ColitisTerminatedNCT04457960Phase 1
• Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory DiseasesCompletedNCT03606499
• Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in KoreaCompletedNCT02229344
• A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT01988961Phase 2
• A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative ColitisCompletedNCT01959282Phase 2
• A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative ColitisCompletedNCT01900574Phase 1
• A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative ColitisCompletedNCT01551290Phase 3
• A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis PatientsCompletedNCT00207688
• A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative ColitisCompletedNCT00096655Phase 3
• A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative ColitisCompletedNCT00036439Phase 3